▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #213 by analyst upside · 2026-09-09
MIST
Milestone Pharmaceuticals Inc.
Healthcare · Market Cap $140M · P/E 0x
ANALYST PRICE TARGET
+420.6%
implied upside to consensus target
Current Price $1.12
Consensus Target $5.86
Bull Target $8.0
Bear Target $2.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
1
Sell
0
52-Week Low $1.0
52-Week High $3.06
YTD Return -45.1%
FUNDAMENTALS
Market Cap $140M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.65
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.0
52-Week High $3.06
Current Price $1.12
Bear Target $2.0
Bull Target $8.0
● Now $1.12 ● Target $5.86
TRADING DATA
Avg Volume 1.4M
YTD Return -45.1%
Analyst Count 7
Consensus Buy
Upside to Target +420.6%
Last Updated 2026-09-09

ANALYST SUMMARY

Milestone Pharmaceuticals Inc. (MIST) is currently trading at $1.12 with a Wall Street consensus price target of $5.86, implying potential upside of 420.6% over the next 12 months. 7 analysts currently cover MIST, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $2.0.

MIST operates in the Healthcare sector with a market capitalisation of $140M. The stock is down 45.1% year-to-date and is currently trading near the lower end of its 52-week range of $1.0 – $3.06.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PLX +315.1%
Protalix BioTherapeutics, Inc.
$214M · P/E 11.5x · Buy
FBIO +305.9%
Fortress Biotech, Inc.
$90M · P/E 1.0x · Buy
PALI +364.6%
Palisade Bio, Inc.
$383M · P/E 3.4x · Buy
VXRT +566.7%
Vaxart, Inc.
$122M · P/E 2.9x · Buy
DWTX +586.3%
Dogwood Therapeutics, Inc.
$69M · P/E 1.1x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MIST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-03 31% win rate (48 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-08-20 40% win rate (10 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-14 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-06 31% win rate (48 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2025-12-16 Building track record
TD Cowen ↑ Upgrade
Hold → Buy 2025-12-15 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-12-15 31% win rate (48 calls)
Wells Fargo ● Initiated
Overweight 2025-09-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →